


- There were 1,098 cases of Tuberculosis (TB) reported in 2022 which represents a 10% increase from the previous year
- Nine people were diagnosed with multidrug-resistant (MDR-TB), and one extensively drug-resistant (XDR-TB) case was reported. MDR-TB and XDR-TB patients receive treatment for three years on average
- 55% of reported cases were Hispanic (of all races), 18% were Asian, 14% were African American, 10% were White, and 3% were among other races
- TB rates are higher along the Texas-Mexico border. The top five countries for non-US-born TB cases are Mexico 36.3%, Vietnam 9.1%, India 7.2%, Honduras 6.9%, and Guatemala 4.6%
- Risk factors among TB cases are Diabetes mellitus 24%, substance use 22%, resident or correctional facility 11%, homelessness 4%, HIV positive 3%, Hepatitis B or C 2%, and COVID-19 1%
- In 2022, there were 50 deaths due to TB



Web

Overall TB Incidence in the United States, 2022



In the case of incidence, the goal for states and cities is to be at or below the national target, because lower incidence of TB is the aim. States/cities are grouped into thirds based on number of TB cases reported.

Centers for Disease Control and Prevention (CDC). Reported Tuberculosis in the United States, 2021. Atlanta, GA: US Department of Health and Human Services, CDC; 2022

- California reported the highest number of TB cases (1,843), followed by Texas with a reported 1,098 cases
- TB epidemiology was characterized by more cases among non-US-born persons newly arrived in the US; higher TB incidence among non-Hispanic American Indian or Alaska Native, and non-Hispanic Native Hawaiian or other Pacific Islander persons
- Nine states and cities report incidence rates above the national target and the national average

Treating Latent TB Infection Prevents TB Disease

Without treatment,

1 in 10 people with latent
TB infection will develop
TB disease.

In 2022, the U.S. reported **8,300 TB cases** with an incidence rate of 2.5 per 100,000.

Eliminating TB requires a comprehensive approach



Engage affected communities and medical providers



Promote effective testing and treatment



Develop new guidance and tools